Successful erlotinib rechallenge in an EGFR‐mutant metastatic non‐small cell lung cancer patient with afatinib‐induced drug rash with eosinophilia and systemic symptoms: A case report
Abstract Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor (EGFR)‐mutant advanced‐stage non‐small cell lung cancer (NSCLC). However, TKIs can cause some severe adverse events, which are more prevalent within first‐generation EGFR‐TKI use than with seco...
Main Authors: | Chung‐Fu Lin, Szu‐Yu Liu, Tzu‐Kun Lo, Julia Yu‐Yun Lee, Po‐Lan Su |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-02-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14276 |
Similar Items
-
Ceftriaxone induced drug rash with eosinophilia and systemic symptoms
by: Vivek S Guleria, et al.
Published: (2014-01-01) -
Eosinophilia as a presenting symptom of the metastatic lung adenocarcinoma with an unknown primary localization
by: Machaczka Maciej, et al.
Published: (2011-10-01) -
Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
by: Sheng‐Yuan Wang, et al.
Published: (2022-01-01) -
Hematological Neoplasms with Eosinophilia
by: Rosario M. Morales-Camacho, et al.
Published: (2024-01-01) -
A Rare Cause of Drug-Induced Skin Rash and Eosinophilia
by: Harun Muglu, et al.
Published: (2018-03-01)